. 2017 Apr 24;12(4):e0175521. doi: 10.1371/journal.pone.0175521

Table 3. Patient and facility characteristics associated with death and lost to follow-up at 12 months after antiretroviral initiation.

	Death12 months after ART Initiation				Lost to Follow-Up 12 months after ART Initiation
	UnadjustedHR	95% CI	AdjustedHR	95% CI	UnadjustedSHR	95% CI	AdjustedSHR	95% CI
Patient Characteristic
Sex
Female	reference
Male	1.5^*	1.3–1.8	1.3^*	1.1–1.5	1.0	0.9–1.1	1.1	1.0–1.2
Age category
15–19	1.2	0.6–2.4	1.0	0.5–2.1	1.1	0.8–1.5	1.0	0.7–1.3
20–24	Reference
25–39	1.0	0.7–1.4	0.9	0.6–1.4	0.7^*	0.6–0.8	0.6^*	0.6–0.7
40–44	1.2	0.9–1.7	1.0	0.7–1.4	0.6^*	0.5–0.7	0.5^*	0.4–0.6
> = 45	1.4	0.9–2.0	1.1	0.7–1.6	0.5^*	0.4–0.6	0.5^*	0.4–0.6
WHO Stage
I/II	Reference
III/VI	1.7^*	1.2–2.4	1.3^{^}	1.0–1.7	1.4^*	1.2–1.5	1.3^*	1.2–1.5
CD4 Count (cells/uL)
<100	4.2^*	3.0–6.1	2.6^*	1.7–4.0	1.0	0.9–1.2	1.1^{^}	1.0–1.3
100–199	2.0^*	1.3–3.1	1.5^{^}	1.0–2.4	0.7^*	0.6–0.8	0.8^*	0.7–1.0
200–349	1.3	0.8–2.0	1.1	0.7–1.7	0.8^*	0.7–0.9	0.8^*	0.7–0.9
>350	reference
BMI (kg/m²)
< 18.5	2.9^*	2.0–4.1	2.0^*	1.3–3.1	1.0	0.9–1.2	1.1	0.9–1.2
≥18.5	Reference
Documented TB
No	Reference
Yes	1.3	0.8–2.1	0.7	0.4–1.2	1.0	0.8–1.2	1.0	0.8–1.3
Calendar year of initiation
2007	Reference
2008	0.4^*	0.2–0.7	0.5^*	0.3–0.8	0.6^*	0.4–0.8	0.6^*	0.4–0.8
2009	0.4^*	0.2–0.6	0.4^*	0.3–0.7	0.6^*	0.4–0.7	0.6^*	0.5–0.8
2010	0.4^*	0.2–0.7	0.5	0.3–1.0	0.5^*	0.3–0.6	0.5^*	0.4-.07
2011	0.2^*	0.1–0.5	0.4^*	0.2–0.8	0.7^*	0.5–0.9	0.7^*	0.5–0.9
2012	0.3^*	0.2–0.5	0.4^*	0.2–0.8	0.8^{^}	0.6–1.0	0.9	0.7–1.1
2013	0.3^*	0.1–0.6	0.5	0.2–1.1	0.9	0.7–1.2	1.0	0.8–1.3
Facility Characteristics
Location
Urban	Reference
Rural	2.4^*	1.5–3.9	1.7	0.9–3.1	0.7^*	0.6–0.7	0.7^*	0.7–0.8
Facility Size
< 1000 patients	Reference
≥1000 patients	0.7	0.3–1.4	0.8	0.5–1.3	1.8^*	1.6–1.9	1.6^*	1.5–1.8

*p value < 0.05,

^p value < 0.10